Aug 10, 2026 7:00am EDT Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights
Aug 3, 2026 7:00am EDT Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.
Jul 27, 2026 7:00am EDT Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026
Jul 15, 2026 9:05am EDT Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models
Jul 13, 2026 7:00am EDT Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA®
Jun 29, 2026 7:25am EDT Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD)
Jun 8, 2026 7:00am EDT Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
May 28, 2026 4:30pm EDT Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
